In this campaign year, politicians have once again started to consider the issue of regulating pharmaceutical pricing policies.  It’s not a new concept but recent practices of certain pharmaceutical companies have given this topic new life.

An article in The New York Times on October 4th reported on several pharmaceutical companies that were buying existing patented therapeutic drugs and dramatically…